These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1242 related articles for article (PubMed ID: 28011478)

  • 41. MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma.
    Tomonari T; Takeishi S; Taniguchi T; Tanaka T; Tanaka H; Fujimoto S; Kimura T; Okamoto K; Miyamoto H; Muguruma N; Takayama T
    Oncotarget; 2016 Feb; 7(6):7207-15. PubMed ID: 26769852
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.
    Kim JS; Choi GH; Jung Y; Kim KM; Jang SJ; Yu ES; Lee HC
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1487-1501. PubMed ID: 29858683
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
    Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
    [TBL] [Abstract][Full Text] [Related]  

  • 44. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib.
    Deng YR; Ma HD; Tsuneyama K; Yang W; Wang YH; Lu FT; Liu CH; Liu P; He XS; Diehl AM; Gershwin ME; Lian ZX
    J Autoimmun; 2013 Oct; 46():25-34. PubMed ID: 23948302
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.
    Chen Y; Feng F; Gao X; Wang C; Sun H; Zhang C; Zeng Z; Lu Y; An L; Qu J; Wang F; Yang Y
    Curr Cancer Drug Targets; 2015; 15(3):176-87. PubMed ID: 25714700
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
    Zhang W; Liu S; Liu K; Ji B; Wang Y; Liu Y
    Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394
    [TBL] [Abstract][Full Text] [Related]  

  • 48. RAF-targeted therapy for hepatocellular carcinoma in the regenerating liver.
    Shi JH; Liu SZ; Wierød L; Scholz H; Anmarkrud JA; Huitfeldt HS; Zhang SJ; Line PD
    J Surg Oncol; 2013 Mar; 107(4):393-401. PubMed ID: 22927239
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
    Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
    PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
    Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
    World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib.
    Ishijima N; Kanki K; Shimizu H; Shiota G
    Cancer Sci; 2015 May; 106(5):567-75. PubMed ID: 25683251
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.
    Horwitz E; Stein I; Andreozzi M; Nemeth J; Shoham A; Pappo O; Schweitzer N; Tornillo L; Kanarek N; Quagliata L; Zreik F; Porat RM; Finkelstein R; Reuter H; Koschny R; Ganten T; Mogler C; Shibolet O; Hess J; Breuhahn K; Grunewald M; Schirmacher P; Vogel A; Terracciano L; Angel P; Ben-Neriah Y; Pikarsky E
    Cancer Discov; 2014 Jun; 4(6):730-43. PubMed ID: 24687604
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
    Kang D; Han Z; Oh GH; Joo Y; Choi HJ; Song JJ
    Yonsei Med J; 2017 Sep; 58(5):899-909. PubMed ID: 28792132
    [TBL] [Abstract][Full Text] [Related]  

  • 54. pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Li J; Shi L; Zhang X; Sun B; Yang Y; Ge N; Liu H; Yang X; Chen L; Qian H; Wu M; Yin Z
    Oncotarget; 2016 Jan; 7(3):2646-59. PubMed ID: 26544731
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines.
    Haga Y; Kanda T; Nakamura M; Nakamoto S; Sasaki R; Takahashi K; Wu S; Yokosuka O
    PLoS One; 2017; 12(3):e0174153. PubMed ID: 28323861
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415.
    Zhang W; Chen B; Zhang Y; Li K; Hao K; Jiang L; Wang Y; Mou X; Xu X; Wang Z
    Biochem Biophys Res Commun; 2017 Jun; 487(3):494-499. PubMed ID: 28366631
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.
    Ou DL; Lee BS; Chang YC; Lin LI; Liou JY; Hsu C; Cheng AL
    PLoS One; 2013; 8(6):e66589. PubMed ID: 23818948
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
    Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
    Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
    Wang W; Xu B; Li Q; Jiang D; Yan S
    Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Melatonin promotes sorafenib-induced apoptosis through synergistic activation of JNK/c-jun pathway in human hepatocellular carcinoma.
    Lin S; Hoffmann K; Gao C; Petrulionis M; Herr I; Schemmer P
    J Pineal Res; 2017 Apr; 62(3):. PubMed ID: 28178378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 63.